Hailin Yang
About Hailin Yang
Hailin Yang serves as the Director at Wave Life Sciences, where he has worked since 2019. He specializes in the development of oligonucleotide therapeutics for solid tumors and has extensive experience in cellular immunology.
Work at Wave Life Sciences
Hailin Yang has been with Wave Life Sciences since 2015, initially serving as a Senior Scientist until 2017. He then progressed to the role of Associate Director, holding this position for seven years. In 2019, he was promoted to Director, where he has continued to contribute to the company's mission. His work focuses on the development of oligonucleotide therapeutics, particularly targeting solid tumors and cancer. Yang's experience encompasses the entire drug development process, from drug target identification to preclinical IND enabling.
Education and Expertise
Hailin Yang earned his Bachelor of Science degree in Biochemistry from East China University of Science and Technology, studying from 1986 to 1990. He furthered his education at the Shanghai Institute of Biochemistry, Chinese Academy of Sciences, where he obtained a Ph.D. in Biochemistry and Molecular Biology from 1990 to 1995. Yang possesses hands-on expertise in cellular immunology, particularly in primary T cell manipulation and characterization, and has over ten years of experience in this field.
Background in Research and Development
Yang has a significant background in research and development, having worked as a Senior Scientist at Dicerna Pharmaceuticals from 2008 to 2015. His role involved innovative research in the field of oligonucleotide therapeutics. He has demonstrated proficiency in experimental study design, execution, and protocol setup, including writing standard operating procedures (SOPs). Yang has also managed and supervised research associates, showcasing his leadership capabilities in a multidisciplinary environment.
Achievements in Drug Development
Throughout his career, Hailin Yang has been involved in the entire drug development process, contributing to various stages from drug target identification to preclinical IND enabling. He has experience in data analysis and result interpretation, particularly with large next-generation sequencing (NGS) and screening data sets. Yang is recognized for his commitment to early adoption of leading technologies, including CRISPR and cancer immune therapies such as CAR-T and TIL.